The Antibiotic Resistance Market To Show Constructive Disruption With US$ 12.6 BPosted by Ashish on April 8th, 2021 Antibiotic resistance is one of the biggest public health concerns today. In the U.S., over 2 million people suffer from an antibiotic-resistant infection annually. Growing mortality rate due to these infections has generated a gateway for pharmaceutical manufacturers to develop novel antibiotics. Fighting this threat is a national and public health priority that needs a collaborative approach among healthcare providers and governments. Human overuse of antibiotics leads to the development of antibiotic resistance, which, in turn, demands newer antibiotics. Escherichia coli and Klebsiella pneumonia are highly resistant to the class of antibiotics called Carbapenem. Carbapenem-resistant Enterobacteriaceae (CRE) infection is a dangerous condition, because these microbes can cause infections in almost all parts of the body. Some of the very severe and common infections include urinary tract infections, ventilator-associated pneumonia bloodstream infections, and intra-abdominal abscesses. These infections are more dangerous as they are resistant to Carbapenem antibiotic drugs, which are considered to be the last resort of defence to treat multidrug-resistant bacterial infections. Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/27895 Companies covered in Antibiotic Resistance Market Report
Like it? Share it!More by this author |